OSE Immunotherapeutics Introduces Investor-Focused Newsletter
OSE Immunotherapeutics Launches Newsletter for Individual Shareholders
NANTES, France – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a pioneering biotechnology company focused on innovative solutions in immuno-oncology and immuno-inflammation, has unveiled its first edition of a newsletter aimed specifically at individual shareholders and investors, both in France and worldwide.
Fiona Olivier, Chief Corporate Affairs & Investor Relations Officer at OSE Immunotherapeutics, shared her enthusiasm: "This year marks a decade since OSE Immunotherapeutics was listed on Euronext Paris. We are excited to present this new platform of communication to cherish our individual shareholders. Beyond regular updates on our company's developments, this newsletter provides a unique opportunity to highlight our dedicated teams and explore topics that typically go unnoticed in press releases. It also serves as a heartfelt gesture of gratitude towards our supportive investor community."
This newsletter will be published regularly in both French and English, ensuring accessibility for a broader audience. Investors can find the newsletter in the 'Investors' section of the OSE Immunotherapeutics website. To stay updated, shareholders are encouraged to subscribe for future editions.
Understanding OSE Immunotherapeutics
ABOUT OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics commits to the development of innovative therapeutic solutions that meet the pressing needs of patients in the realms of immuno-oncology and immuno-inflammation. By partnering with top-tier academic institutions and biopharmaceutical organizations, OSE Immunotherapeutics is on a mission to bring transformative medicines to market for those suffering from serious health conditions. The company operates from locations in Nantes and Paris and is publicly listed on Euronext.
Company Vision and Commitment
With a focus on pioneering first-in-class assets, OSE Immunotherapeutics is dedicated to advancing research that has the potential to redefine treatment paradigms in immunotherapy. Their commitment extends to engaging with the community and enhancing investor relations through informational channels like the recently launched newsletter.
Engaging with Shareholders
The establishment of this newsletter is a step towards fostering closer ties with shareholders. OSE Immunotherapeutics aims to ensure that their investors are kept well-informed and engaged with the company's strategic directions and milestones.
Contact Information for Further Inquiry
For additional information or inquiries, investors can reach out to the following contacts:
Fiona Olivier
fiona.olivier@ose-immuno.com
Sylvie Détry
sylvie.detry@ose-immuno.com
Media Contacts
France Media Contact:
FP2COM
Florence Portejoie
fportejoie@fp2com.fr
+33 6 07 768 283
U.S. Media Contact:
RooneyPartners LLC
Kate Barrette
kbarrette@rooneypartners.com
+1 212 223 0561
Frequently Asked Questions
What is the purpose of the newsletter from OSE Immunotherapeutics?
The newsletter is designed to provide individual shareholders with updates, insights, and appreciation directly from the company.
How often will the newsletter be published?
The newsletter will be published regularly, ensuring timely updates on company developments.
In which languages will the newsletter be available?
The newsletter will be available in both French and English to cater to a broader audience.
How can investors subscribe to the newsletter?
Investors can subscribe to the newsletter through the 'Investors' section of the OSE Immunotherapeutics website.
What are the main therapeutic areas of focus for OSE Immunotherapeutics?
OSE Immunotherapeutics focuses on developing assets in immuno-oncology and immuno-inflammation therapies.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
